Karyopharm Therapeutics Inc.
KPTI US48576U1060
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -62% | -52% | -74% | -24% | -4% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Abate Kristin DIR |
6.30 USD |
362 Sold |
2,279 USD |
01/10/2025 | 01/10/2025 |
| Poulton Stuart EX VP |
6.43 USD |
401 Sold |
2,578 USD |
12/09/2025 | 15/09/2025 |
| Abate Kristin DIR |
6.43 USD |
23 Sold |
148 USD |
12/09/2025 | 15/09/2025 |
| Rangwala Reshma EX VP |
6.43 USD |
408 Sold |
2,623 USD |
12/09/2025 | 15/09/2025 |
| Mano Michael VP |
6.43 USD |
234 Sold |
1,505 USD |
12/09/2025 | 15/09/2025 |
| Cheng Sohanya Roshan EX VP |
6.43 USD |
325 Sold |
2,090 USD |
12/09/2025 | 15/09/2025 |
| Paulson Richard A. CEO |
6.43 USD |
1,257 Sold |
8,083 USD |
12/09/2025 | 15/09/2025 |
| Abate Kristin CCO |
6.78 USD |
12 Sold |
81 USD |
03/09/2025 | 03/09/2025 |
| Poulton Stuart EX VP |
4.37 USD |
191 Sold |
835 USD |
29/07/2025 | 29/07/2025 |
| Abate Kristin CCO |
4.00 USD |
238 Sold |
952 USD |
22/07/2025 | 22/07/2025 |